Colorectal Cancer | Specialty

The Influx of Younger Patients With Advanced CRC

March 29th 2019

Sequencing for BRAF+, RAS+, HER2- Left-Sided CRC

March 29th 2019

Multidisciplinary Approach to Resection in mCRC

March 29th 2019

Tissue-Based Testing Versus Liquid Biopsy in mCRC

March 29th 2019

Considering the Basics in Newly Diagnosed mCRC

March 29th 2019

Molecular Markers Gaining Greater Influence in CRC Paradigm

March 27th 2019

Mohamed E. Salem, MD, highlights ongoing research efforts to potentially improve survival in patients with metastatic colorectal cancer.

Testing, Treatment Options Added to NCCN CRC Guidelines

March 25th 2019

A theme of the 2019 NCCN Annual Conference was the expansion of biomarker testing to guide treatment, and a review of brand-new changes for guidelines in colorectal cancer was no different.

Key Trials Seek to Expand on Efficacy, Tolerability of Treatment Regimens in Refractory CRC

March 22nd 2019

Iman Imanirad, MD, discusses these trials in depth and their impact on patients with refractory metastatic colorectal cancer.

Dr. Mahipal on Treatment of Newly Diagnosed mCRC

March 22nd 2019

Amit Mahipal, MBBS, professor of medicine, Mayo Clinic, discusses the treatment of patients with newly diagnosed metastatic colorectal cancer.

GI Oncologist Sheds Light on Present and Future of mCRC Treatment

March 21st 2019

Amit Mahipal, MBBS, discusses navigating the complex treatment paradigm of metastatic colorectal cancer and sheds light on how recent advances are impacting the outlook of those affected by the disease.

Encorafenib/Binimetinib-based Triplet Added to NCCN Guidelines for BRAF+ CRC

March 18th 2019

The NCCN has updated their clinical practice guidelines for the treatment of patients with colorectal cancer to include the regimen of encorafenib and binimetinib plus EGFR inhibition with either cetuximab or panitumumab as a Category 2a treatment recommendation for patients with BRAF V600E–mutant metastatic colorectal cancer, after failure of 1 or 2 lines of therapy for metastatic disease.

Dr. Strickler on Therapies for Rare Variants of Relapsed/Refractory CRC

March 13th 2019

John Strickler, MD, assistant professor of medicine at Duke University School of Medicine, gastrointestinal oncologist, Duke Cancer Institute, discusses therapies for rare variants of relapsed/refractory colorectal cancer.

Expert Highlights Evidence-Based Decision-Making in mCRC

March 11th 2019

Michael S. Lee, MD, sheds light on the treatment options available in the metastatic colorectal cancer space and highlights strategies poised to improve patient outcomes.

Dr. Jiang on the Future of Immunotherapy in Microsatellite Stable Colorectal Cancer

March 9th 2019

Yixing Jiang, BM, PhD, associate professor of medicine, director, Gastrointestinal Medical Oncology Marlene Stewart Greenebaum Cancer Center, University of Maryland School of Medicine, discusses the future of immunotherapy in microsatellite stable (MSS) colorectal cancer (CRC).

Strickler Stresses Continued Focus on Molecular Subtypes in mCRC

March 9th 2019

John Strickler, MD, highlights important data in the metastatic colorectal cancer space and challenges that remain for oncologists working in the field.

Dr. Marshall on Personalized Chemotherapy in CRC

March 5th 2019

John L. Marshall, MD, chief, Division of Hematology/Oncology, Medstar Georgetown University Hospital director, Otto J. Ruesch Center for the Cure of Gastrointestinal Cancer, Georgetown-Lombardi Comprehensive Cancer Center, discusses personalized chemotherapy in the treatment of patients with colorectal cancer.

Management of Metastatic CRC Rooted in Molecular Subsets

March 5th 2019

John L. Marshall, MD, discusses the current and future scope of metastatic colorectal cancer.

EU Panel Backs Extended Pembrolizumab Dosing Schedule for Single-Agent Indications

March 5th 2019

The European Medicines Agency’s Committee for Medicinal Products for Human Use has adopted a positive opinion for a new extended dosing schedule for pembrolizumab for all of the PD-1 inhibitor’s monotherapy indications in the European Union.

Immunotherapy, Chemo Approaches Continue to Build in CRC and Pancreatic Cancer

March 5th 2019

Douglas A. Nelson, MD, discusses key advances made in the treatment of patients with colorectal cancer and pancreatic cancer, and sheds light on remaining challenges in these paradigms.

Younger Patients With CRC Misdiagnosed, Diagnosed at Later Stages

February 28th 2019

Many younger patients see more than one doctor and face misdiagnoses before being given a diagnosis of colorectal cancer.